Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies

Tomasz (Tom) Beer, Catherine M. Tangen, Craig R. Nichols, Kim A. Margolin, Robert Dreicer, William T. Stephenson, David I. Quinn, Derek Raghavan, E. David Crawford

    Research output: Contribution to journalArticle

    26 Citations (Scopus)

    Abstract

    BACKGROUND. To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed. METHODS. Twenty patients were treated with arsenic trioxide at a dose of 0.25 mg/kg/day and administered intravenously over 1 to 2 hours on Days 1-5 and repeated every 28 days. RESULTS. There were no complete or partial responses. The median progression-free survival was 1 month and the median overall survival was 2 months. Three patients died as a result of adverse events believed to be possibly related to treatment: ventricular arrhythmia, adult respiratory distress syndrome, and pneumonitis. CONCLUSIONS. In the current study, arsenic trioxide in the dose regimen and schedule employed was found to have no activity in men with refractory germ cell malignancies. Treatment was associated with severe toxicity. Dismal overall survival reflects the poor outcome in this patient group and highlights the acute need for new agents with activity in refractory germ cell neoplasms.

    Original languageEnglish (US)
    Pages (from-to)2624-2629
    Number of pages6
    JournalCancer
    Volume106
    Issue number12
    DOIs
    StatePublished - Jun 15 2006

    Fingerprint

    Germ Cells
    Germ Cell and Embryonal Neoplasms
    Neoplasms
    Survival
    Adult Respiratory Distress Syndrome
    Disease-Free Survival
    Cardiac Arrhythmias
    Pneumonia
    Appointments and Schedules
    Therapeutics
    Safety
    arsenic trioxide

    Keywords

    • Arsenic trioxide
    • Germ cell cancer
    • Refractory
    • Treatment outcome

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Beer, T. T., Tangen, C. M., Nichols, C. R., Margolin, K. A., Dreicer, R., Stephenson, W. T., ... Crawford, E. D. (2006). Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer, 106(12), 2624-2629. https://doi.org/10.1002/cncr.21925

    Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. / Beer, Tomasz (Tom); Tangen, Catherine M.; Nichols, Craig R.; Margolin, Kim A.; Dreicer, Robert; Stephenson, William T.; Quinn, David I.; Raghavan, Derek; Crawford, E. David.

    In: Cancer, Vol. 106, No. 12, 15.06.2006, p. 2624-2629.

    Research output: Contribution to journalArticle

    Beer, TT, Tangen, CM, Nichols, CR, Margolin, KA, Dreicer, R, Stephenson, WT, Quinn, DI, Raghavan, D & Crawford, ED 2006, 'Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies', Cancer, vol. 106, no. 12, pp. 2624-2629. https://doi.org/10.1002/cncr.21925
    Beer TT, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT et al. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 2006 Jun 15;106(12):2624-2629. https://doi.org/10.1002/cncr.21925
    Beer, Tomasz (Tom) ; Tangen, Catherine M. ; Nichols, Craig R. ; Margolin, Kim A. ; Dreicer, Robert ; Stephenson, William T. ; Quinn, David I. ; Raghavan, Derek ; Crawford, E. David. / Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. In: Cancer. 2006 ; Vol. 106, No. 12. pp. 2624-2629.
    @article{e9bfc69086e744718a1950d462cb91fd,
    title = "Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies",
    abstract = "BACKGROUND. To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed. METHODS. Twenty patients were treated with arsenic trioxide at a dose of 0.25 mg/kg/day and administered intravenously over 1 to 2 hours on Days 1-5 and repeated every 28 days. RESULTS. There were no complete or partial responses. The median progression-free survival was 1 month and the median overall survival was 2 months. Three patients died as a result of adverse events believed to be possibly related to treatment: ventricular arrhythmia, adult respiratory distress syndrome, and pneumonitis. CONCLUSIONS. In the current study, arsenic trioxide in the dose regimen and schedule employed was found to have no activity in men with refractory germ cell malignancies. Treatment was associated with severe toxicity. Dismal overall survival reflects the poor outcome in this patient group and highlights the acute need for new agents with activity in refractory germ cell neoplasms.",
    keywords = "Arsenic trioxide, Germ cell cancer, Refractory, Treatment outcome",
    author = "Beer, {Tomasz (Tom)} and Tangen, {Catherine M.} and Nichols, {Craig R.} and Margolin, {Kim A.} and Robert Dreicer and Stephenson, {William T.} and Quinn, {David I.} and Derek Raghavan and Crawford, {E. David}",
    year = "2006",
    month = "6",
    day = "15",
    doi = "10.1002/cncr.21925",
    language = "English (US)",
    volume = "106",
    pages = "2624--2629",
    journal = "Cancer",
    issn = "0008-543X",
    publisher = "John Wiley and Sons Inc.",
    number = "12",

    }

    TY - JOUR

    T1 - Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies

    AU - Beer, Tomasz (Tom)

    AU - Tangen, Catherine M.

    AU - Nichols, Craig R.

    AU - Margolin, Kim A.

    AU - Dreicer, Robert

    AU - Stephenson, William T.

    AU - Quinn, David I.

    AU - Raghavan, Derek

    AU - Crawford, E. David

    PY - 2006/6/15

    Y1 - 2006/6/15

    N2 - BACKGROUND. To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed. METHODS. Twenty patients were treated with arsenic trioxide at a dose of 0.25 mg/kg/day and administered intravenously over 1 to 2 hours on Days 1-5 and repeated every 28 days. RESULTS. There were no complete or partial responses. The median progression-free survival was 1 month and the median overall survival was 2 months. Three patients died as a result of adverse events believed to be possibly related to treatment: ventricular arrhythmia, adult respiratory distress syndrome, and pneumonitis. CONCLUSIONS. In the current study, arsenic trioxide in the dose regimen and schedule employed was found to have no activity in men with refractory germ cell malignancies. Treatment was associated with severe toxicity. Dismal overall survival reflects the poor outcome in this patient group and highlights the acute need for new agents with activity in refractory germ cell neoplasms.

    AB - BACKGROUND. To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed. METHODS. Twenty patients were treated with arsenic trioxide at a dose of 0.25 mg/kg/day and administered intravenously over 1 to 2 hours on Days 1-5 and repeated every 28 days. RESULTS. There were no complete or partial responses. The median progression-free survival was 1 month and the median overall survival was 2 months. Three patients died as a result of adverse events believed to be possibly related to treatment: ventricular arrhythmia, adult respiratory distress syndrome, and pneumonitis. CONCLUSIONS. In the current study, arsenic trioxide in the dose regimen and schedule employed was found to have no activity in men with refractory germ cell malignancies. Treatment was associated with severe toxicity. Dismal overall survival reflects the poor outcome in this patient group and highlights the acute need for new agents with activity in refractory germ cell neoplasms.

    KW - Arsenic trioxide

    KW - Germ cell cancer

    KW - Refractory

    KW - Treatment outcome

    UR - http://www.scopus.com/inward/record.url?scp=33745219500&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33745219500&partnerID=8YFLogxK

    U2 - 10.1002/cncr.21925

    DO - 10.1002/cncr.21925

    M3 - Article

    VL - 106

    SP - 2624

    EP - 2629

    JO - Cancer

    JF - Cancer

    SN - 0008-543X

    IS - 12

    ER -